Cyramza
(Ramucirumab)Phase 3Monoclonal antibody
Eli LillyRamucirumab is used to treat certain types of advanced cancers, including stomach cancer, lung cancer, and colorectal cancer, by blocking a protein that helps tumors grow and spread.[1] Cyramza is currently being investigated across 42 indications[3], with its most advanced program in Phase 3.[1]
Cyramza is one of 759 small molecule programs targeting Gastroesophageal Junction Adenocarcinoma. It is currently in Phase 3.
42
Indications
135
Total Trials
42
Active Trials
758
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 42 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Cyramza
Eli LillyPhase 3
Avastin
BBio-Thera Solutions
Preclinical
Lexiscan
AstellasPreclinical
Lupron
EEastern Cooperative Oncology Group
Preclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
QS21
MMemorial Sloan Kettering Cancer Center
Preclinical
Apatinib Mesylate
BBukwang Pharmaceutical
Preclinical
Beta Blocker
WWeill Medical College of Cornell University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Q4 2026
Phase 1/2Active, not recruiting
Desmoplastic Small Round Cell Tumor
NCT04145349
Phase 3Active, not recruiting
Gastric Cancer
NCT06346392
Phase 3Active, not recruiting
Metastatic NSCLC
NCT02411448
Phase 2Active, not recruiting
Biliary Tract Cancer
NCT02711553
Phase 2Recruiting
Esophageal Adenocarcinoma
NCT04069273
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer19 trials
Show 16 more trials
Gastric Cancer9 trials
A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06564298·39 enrolled
Show 6 more trials
Esophageal Cancer6 trials
Gastroesophageal Junction Cancer6 trials
Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients
Active, not recruiting·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT03760822·112 enrolled
Show 3 more trials
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
Recruiting·—·Phase 2·NCT04660760·116 enrolled
Gastroesophageal Junction Adenocarcinoma5 trials
60 more indications
Esophageal Adenocarcinoma5 trials
Lung Cancer5 trials
Gastric Adenocarcinoma4 trials
Adenocarcinoma4 trials
Breast Cancer3 trials
Hepatocellular Carcinoma3 trials
Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 1·NCT05856864·30 enrolled
Advanced Cancer3 trials
Advanced Solid Tumors2 trials
Metastatic NSCLC2 trials
Tics2 trials
Solid Tumors2 trials
Liver Cancer2 trials
Immune2 trials
Pancreatic Cancer2 trials
Pembrolizumab2 trials
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
Recruiting·—·Phase 2·NCT04332367·59 enrolled
Mesothelioma1 trial
Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
Terminated·—·Phase 2·NCT03502746·34 enrolled
GastroEsophageal Junction (GEJ) Cancer1 trial
Clinical Trial1 trial
Head and Neck Squamous Cell Carcinoma1 trial
Locally Advanced1 trial
Biliary Tract Cancer1 trial
Gastrointestinal1 trial
Combination Therapy1 trial
Gemcitabine1 trial
Nivolumab1 trial
Renal Cell Carcinoma1 trial
Advanced Cancers1 trial
Carcinoid Tumor1 trial
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Completed·—·Phase 2·NCT02795858·43 enrolled
Urothelial Cancer1 trial
Fluorouracil1 trial
Patients With Solid Tumors1 trial
Advanced Refractory Solid Tumors1 trial
Paclitaxel1 trial
Renal Cancer1 trial
Peritoneal Metastases1 trial
Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases
Recruiting·—·Phase 1·NCT06675136·30 enrolled
Synovial Sarcoma1 trial
Gastroesophageal Junction1 trial
Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca
Active, not recruiting·—·Phase 1/2·NCT04921904·8 enrolled
Patients With Advanced Solid Tumors1 trial
Recurrent NSCLC1 trial
Gastric1 trial
FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)
Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2/3·NCT02661971·180 enrolled
Stomach Cancer1 trial
Transitional Cell Carcinoma1 trial
Biliary Cancer1 trial
PD-L1 Positive1 trial
Desmoplastic Small Round Cell Tumor1 trial
Pancreatic Adenocarcinoma1 trial
Refractory Solid Tumors1 trial
Glioblastoma Multiforme1 trial
Advanced NSCLC1 trial
HER2-Negative1 trial
Gastroesophageal Adenocarcinoma1 trial
Advanced Gastric or EGJ Cancer1 trial
Ramucirumab Plus Irinotecan / Leucovorin / 5-FU Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed One Prior Line of Palliative Chemotherapy - The Phase II/III RAMIRIS Study
Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Preclinical·NCT03081143·429 enrolled
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma1 trial
Solid Tumor1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Apr 21, 2014
CYRAMZA
BLA BLA125477
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ramucirumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]